Literature DB >> 30481318

An ultra-high affinity ligand of HIV-1 TAR reveals the RNA structure recognized by P-TEFb.

Matthew D Shortridge1, Paul T Wille2, Alisha N Jones1, Amy Davidson1, Jasmina Bogdanovic3, Eric Arts2, Jonathan Karn2, John A Robinson3, Gabriele Varani1.   

Abstract

The HIV-1 trans-activator protein Tat binds the trans-activation response element (TAR) to facilitate recruitment of the super elongation complex (SEC) to enhance transcription of the integrated pro-viral genome. The Tat-TAR interaction is critical for viral replication and the emergence of the virus from the latent state, therefore, inhibiting this interaction has long been pursued to discover new anti-viral or latency reversal agents. However, discovering active compounds that directly target RNA with high affinity and selectivity remains a significant challenge; limiting pre-clinical development. Here, we report the rational design of a macrocyclic peptide mimic of the arginine rich motif of Tat, which binds to TAR with low pM affinity and 100-fold selectivity against closely homologous RNAs. Despite these unprecedented binding properties, the new ligand (JB181) only moderately inhibits Tat-dependent reactivation in cells and recruitment of positive transcription elongation factor (P-TEFb) to TAR. The NMR structure of the JB181-TAR complex revealed that the ligand induces a structure in the TAR loop that closely mimics the P-TEFb/Tat1:57/AFF4/TAR complex. These results strongly suggest that high-affinity ligands which bind the UCU bulge are not likely to inhibit recruitment of the SEC and suggest that targeting of the TAR loop will be an essential feature of effective Tat inhibitors.
© The Author(s) 2018. Published by Oxford University Press on behalf of Nucleic Acids Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 30481318      PMCID: PMC6379670          DOI: 10.1093/nar/gky1197

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  54 in total

1.  Simultaneous recognition of HIV-1 TAR RNA bulge and loop sequences by cyclic peptide mimics of Tat protein.

Authors:  Amy Davidson; Thomas C Leeper; Zafiria Athanassiou; Krystyna Patora-Komisarska; Jonathan Karn; John A Robinson; Gabriele Varani
Journal:  Proc Natl Acad Sci U S A       Date:  2009-07-07       Impact factor: 11.205

2.  Role of RNA structure in arginine recognition of TAR RNA.

Authors:  J D Puglisi; L Chen; A D Frankel; J R Williamson
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-15       Impact factor: 11.205

Review 3.  The future of peptide-based drugs.

Authors:  David J Craik; David P Fairlie; Spiros Liras; David Price
Journal:  Chem Biol Drug Des       Date:  2013-01       Impact factor: 2.817

4.  Structure of a low-population binding intermediate in protein-RNA recognition.

Authors:  Aditi N Borkar; Michael F Bardaro; Carlo Camilloni; Francesco A Aprile; Gabriele Varani; Michele Vendruscolo
Journal:  Proc Natl Acad Sci U S A       Date:  2016-06-10       Impact factor: 11.205

5.  Small Molecule-Based Pattern Recognition To Classify RNA Structure.

Authors:  Christopher S Eubanks; Jordan E Forte; Gary J Kapral; Amanda E Hargrove
Journal:  J Am Chem Soc       Date:  2016-12-22       Impact factor: 15.419

6.  Peptidomimetic antibiotics target outer-membrane biogenesis in Pseudomonas aeruginosa.

Authors:  Nityakalyani Srinivas; Peter Jetter; Bernhard J Ueberbacher; Martina Werneburg; Katja Zerbe; Jessica Steinmann; Benjamin Van der Meijden; Francesca Bernardini; Alexander Lederer; Ricardo L A Dias; Pauline E Misson; Heiko Henze; Jürg Zumbrunn; Frank O Gombert; Daniel Obrecht; Peter Hunziker; Stefan Schauer; Urs Ziegler; Andres Käch; Leo Eberl; Kathrin Riedel; Steven J DeMarco; John A Robinson
Journal:  Science       Date:  2010-02-19       Impact factor: 47.728

7.  A Macrocyclic Peptide Ligand Binds the Oncogenic MicroRNA-21 Precursor and Suppresses Dicer Processing.

Authors:  Matthew D Shortridge; Matthew J Walker; Tom Pavelitz; Yu Chen; Wen Yang; Gabriele Varani
Journal:  ACS Chem Biol       Date:  2017-05-02       Impact factor: 5.100

8.  Design of beta-hairpin peptidomimetics that inhibit binding of alpha-helical HIV-1 Rev protein to the rev response element RNA.

Authors:  Kerstin Moehle; Zafiria Athanassiou; Krystyna Patora; Amy Davidson; Gabriele Varani; John A Robinson
Journal:  Angew Chem Int Ed Engl       Date:  2007       Impact factor: 15.336

9.  Designing Well-Structured Cyclic Pentapeptides Based on Sequence-Structure Relationships.

Authors:  Diana P Slough; Sean M McHugh; Ashleigh E Cummings; Peng Dai; Bradley L Pentelute; Joshua A Kritzer; Yu-Shan Lin
Journal:  J Phys Chem B       Date:  2018-03-28       Impact factor: 2.991

10.  Essential structural requirements for specific recognition of HIV TAR RNA by peptide mimetics of Tat protein.

Authors:  Amy Davidson; Krystyna Patora-Komisarska; John A Robinson; Gabriele Varani
Journal:  Nucleic Acids Res       Date:  2010-08-19       Impact factor: 16.971

View more
  14 in total

1.  Design of RNA-targeting macrocyclic peptides.

Authors:  Matthew J Walker; Gabriele Varani
Journal:  Methods Enzymol       Date:  2019-06-13       Impact factor: 1.600

Review 2.  Methods to identify and optimize small molecules interacting with RNA (SMIRNAs).

Authors:  Andrei Ursu; Simon Vézina-Dawod; Matthew D Disney
Journal:  Drug Discov Today       Date:  2019-07-26       Impact factor: 7.851

Review 3.  Face-time with TAR: Portraits of an HIV-1 RNA with diverse modes of effector recognition relevant for drug discovery.

Authors:  Sai Shashank Chavali; Rachel Bonn-Breach; Joseph E Wedekind
Journal:  J Biol Chem       Date:  2019-05-12       Impact factor: 5.157

Review 4.  Cure and Long-Term Remission Strategies.

Authors:  Luisa Mori; Susana T Valente
Journal:  Methods Mol Biol       Date:  2022

5.  The TAR binding dynamics and its implication in Tat degradation mechanism.

Authors:  Shangbo Ning; Chengwei Zeng; Chen Zeng; Yunjie Zhao
Journal:  Biophys J       Date:  2021-11-09       Impact factor: 4.033

6.  SILCS-RNA: Toward a Structure-Based Drug Design Approach for Targeting RNAs with Small Molecules.

Authors:  Abhishek A Kognole; Anthony Hazel; Alexander D MacKerell
Journal:  J Chem Theory Comput       Date:  2022-08-01       Impact factor: 6.578

Review 7.  CDK9 keeps RNA polymerase II on track.

Authors:  Sylvain Egloff
Journal:  Cell Mol Life Sci       Date:  2021-06-19       Impact factor: 9.261

Review 8.  How 'Protein-Docking' Translates into the New Emerging Field of Docking Small Molecules to Nucleic Acids?

Authors:  Francesca Tessaro; Leonardo Scapozza
Journal:  Molecules       Date:  2020-06-13       Impact factor: 4.411

Review 9.  NMR Studies of Retroviral Genome Packaging.

Authors:  Patricia S Boyd; Janae B Brown; Joshua D Brown; Jonathan Catazaro; Issac Chaudry; Pengfei Ding; Xinmei Dong; Jan Marchant; Colin T O'Hern; Karndeep Singh; Canessa Swanson; Michael F Summers; Saif Yasin
Journal:  Viruses       Date:  2020-09-30       Impact factor: 5.048

Review 10.  Addressing an HIV cure in LMIC.

Authors:  Sherazaan D Ismail; Joshua Pankrac; Emmanuel Ndashimye; Jessica L Prodger; Melissa-Rose Abrahams; Jamie F S Mann; Andrew D Redd; Eric J Arts
Journal:  Retrovirology       Date:  2021-08-03       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.